C. Ballow

发表

In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.

Jerome J. Schentag, R. Jones, D. M. Johnson, 1998, Diagnostic microbiology and infectious disease.

Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.

Jerome J. Schentag, R. Jones, D. M. Johnson, 1997, Diagnostic microbiology and infectious disease.

Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.

M. Battegay, Yongmei Li, J. Kort, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Seizure Activity Associated with Imipenem Use: Clinical Case Reports and Review of the Literature

C. Ballow, R. J. Leo, Charles H. Ballow, 1991, DICP : the annals of pharmacotherapy.

Azithromycin: The First Azalide Antibiotic

C. Ballow, G. Amsden, 1992, The Annals of pharmacotherapy.

A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia.

Ronald N. Jones, R. Jones, S. Bhavnani, 2000, Diagnostic microbiology and infectious disease.

Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe).

R. Jones, A. Bolmstrôm, C. Ballow, 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

A multicenter evaluation of linezolid antimicrobial activity in North America.

Ronald N. Jones, D. Biedenbach, C. Ballow, 2002, Diagnostic microbiology and infectious disease.

Tissue-directed pharmacokinetics.

Jerome J. Schentag, C. Ballow, 1991, The American journal of medicine.

New agents for Gram-positive bacteria.

S. Bhavnani, C. Ballow, 2000, Current opinion in microbiology.

Mathematical Examination of Dual Individualization Principles (II): The Rate of Bacterial Eradication at the Same Area under the Inhibitory Curve is More Rapid for Ciprofloxacin Than for Cefmenoxime

Jerome J. Schentag, T. Goss, A. Forrest, 1994, The Annals of pharmacotherapy.

Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance Group.

Jerome J. Schentag, C. Ballow, 1992, Diagnostic microbiology and infectious disease.

Pharmacokinetics of Oral Azithromycin in Serum, Urine, Polymorphonuclear Leucocytes and Inflammatory vs Non-Inflammatory Skin Blisters in Healthy Volunteers

A. Forrest, C. Ballow, G. Amsden, 1998, Clinical drug investigation.

Effects of a State‐ and Use‐Dependent Nav1.7 Channel Blocker on Ambulatory Blood Pressure: A Randomized, Controlled Crossover Study

W. White, H. Naik, J. Palmer, 2018, Journal of clinical pharmacology.

Legionella urinary antigen testing: potential impact on diagnosis and antibiotic therapy.

A. Kashuba, C. Ballow, A. Kashuba, 1996, Diagnostic microbiology and infectious disease.

Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study.

R. Jones, H. Sader, D. Biedenbach, 2001, Brazilian Journal of Infectious Diseases.

Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States.

Ronald N. Jones, R. Jones, D. Biedenbach, 2001, Diagnostic microbiology and infectious disease.

Safety, Pharmacokinetic, Immunogenicity, and Pharmacodynamic Responses in Healthy Volunteers Following a Single Intravenous Injection of Purified Staphylococcal Protein A

E. Bernton, C. Ballow, D. Haughey, 2013, Journal of clinical pharmacology.

Fosamprenavir plus Ritonavir Increases Plasma Ketoconazole and Ritonavir Exposure, while Amprenavir Exposure Remains Unchanged

M. Shelton, C. Ballow, Eric Lewis, 2007, Antimicrobial Agents and Chemotherapy.

Inhibition of mixed-function oxidation in perfused rat liver by fluoroacetate treatment.

R. Thurman, F. Kauffman, C. Ballow, 1984, Biochemical pharmacology.

Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.

J J Schentag, R N Jones, Jerome J. Schentag, 1998, Diagnostic microbiology and infectious disease.

Population Pharmacokinetic Methods to Optimise Antibiotic Effects

Jerome J. Schentag, C. Ballow, G. Amsden, 1993 .

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

J J Schentag, A Forrest, Jerome J. Schentag, 1993, Antimicrobial Agents and Chemotherapy.

Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific.

Ronald N. Jones, J. Turnidge, J. Bell, 2003, The Journal of antimicrobial chemotherapy.

Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox(R) antimicrobial potency study in Latin America (LA-ZAPS).

Ronald N. Jones, F. Rossi, D. Biedenbach, 2002, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

Corynebacterium xerosis septic arthritis.

P. Valenstein, C. Ballow, W. Greene, 1988, American journal of clinical pathology.

Pharmacodynamic Evaluation of Factors Associated with the Development of Bacterial Resistance in Acutely Ill Patients during Therapy

Jerome J. Schentag, S. Bhavnani, A. Forrest, 1998, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers

C. Hendrix, D. Stein, C. Ballow, 2004, AIDS.

Pharmacokinetics of BILR 355 after Multiple Oral Doses Coadministered with a Low Dose of Ritonavir

T. Macgregor, C. Ballow, L. Rowland, 2008, Antimicrobial Agents and Chemotherapy.

Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of BCH-10652 in Healthy Adult Males

David E. Martin, Patrick F. Smith, A. Forrest, 2000, Antimicrobial Agents and Chemotherapy.

Safety and Pharmacokinetics of Bevirimat (PA-457), a Novel Inhibitor of Human Immunodeficiency Virus Maturation, in Healthy Volunteers

David E. Martin, Judy Doto, J. Wilton, 2007, Antimicrobial Agents and Chemotherapy.

Safety and Pharmacokinetics of Bevirimat (PA-457), a Novel Inhibitor of Human Immunodeﬁciency Virus Maturation, in Healthy Volunteers (cid:1)

David E. Martin, Judy Doto, J. Wilton, 2007 .

Absolute Bioavailability and Disposition of (−) and (+) 2′-Deoxy- 3′-Oxa-4′-Thiocytidine (dOTC) following Single Intravenous and Oral Doses of Racemic dOTC in Humans

David E. Martin, Patrick F. Smith, A. Forrest, 2000, Antimicrobial Agents and Chemotherapy.

Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin

Jerome J. Schentag, A. Forrest, D. Nix, 1993, Antimicrobial Agents and Chemotherapy.

Comparison of the Plasma, Urine and Blister Fluid Pharmacokinetics of Clarithromycin and Azithromycin in Normal Subjects

A. Forrest, C. Ballow, G. Amsden, 1997 .

Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables.

Jerome J. Schentag, C. Peloquin, A. Forrest, 2000, The Journal of antimicrobial chemotherapy.

Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients.

Jerome J. Schentag, A. Forrest, P. F. Smith, 2001, Clinical therapeutics.

Prospective Validation of an Optimal Sparse Plasma‐Sampling Strategy for Estimating Ciprofloxacin Pharmacokinetics

C. Ballow, G. Amsden, G W Amsden, 1996, Pharmacotherapy.

Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime

A. Forrest, C. Ballow, A. Kashuba, 1996, Antimicrobial agents and chemotherapy.

Efficacy of a Methylphenidate Transdermal System Versus t.i.d. Methylphenidate in a Laboratory Setting

Mario A. González, W. Pelham, E. Gnagy, 2011, Journal of attention disorders.

Methylphenidate in a Laboratory Setting

Mario A. González, W. Pelham, E. Gnagy, 2010 .

Multiple-Dose Pharmacokinetics and Safety of Bevirimat, a Novel Inhibitor of HIV Maturation, in Healthy Volunteers

David E. Martin, Judy Doto, C. Ballow, 2007, Clinical pharmacokinetics.

Effects of 3-methylcholanthrene on oxidized nicotinamide-adenine dinucleotide phosphatedependent dehydrogenases and selected metabolites in perfused rat liver.

S. Belinsky, R. Thurman, F. Kauffman, 1980, Biochemical pharmacology.

Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory.

J J Schentag, T J Cumbo, Jerome J. Schentag, 1993, Diagnostic microbiology and infectious disease.

Development ofa Population Pharmacokinetic Modeland Optimal Sampling Strategies forIntravenous Ciprofloxacin

A. Forrest, C. Ballow, 1993 .

Antibiotic dosing issues in lower respiratory tract infection: population-derived area under inhibitory curve is predictive of efficacy.

J J Schentag, A Forrest, Jerome J. Schentag, 1999, The Journal of antimicrobial chemotherapy.

Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: In vitro and in vivo correlation

D. Tweedie, M. Battegay, Naitee Ting, 2015, Journal of clinical pharmacology.

Absolute bioavailability of moxifloxacin.

H. Stass, J. T. Sullivan, J. Lettieri, 1999, Clinical therapeutics.

Modeling the response of pneumonia to antimicrobial therapy

Jerome J. Schentag, A. Forrest, C. Ballow, 1997, Antimicrobial agents and chemotherapy.

Effect of Telavancin on the Pharmacokinetics of the Cytochrome P450 3A Probe Substrate Midazolam: A Randomized, Double‐Blind, Crossover Study in Healthy Subjects

S. Barriere, C. Ballow, M. Kitt, 2010, Pharmacotherapy.

Effect of Food on the Pharmacokinetics of (‐) and (+) dOTC When Administered as an Oral Racemate

Patrick F. Smith, A. Forrest, C. Ballow, 2002, Journal of clinical pharmacology.